drugset / Trial / NCT01866293
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
Timeline
- Start
- 2013-05-28
- Primary completion
- 2016-08-18
- Completion
- 2016-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | Oral |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |